Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Financial results for the first half of 2009: significant investment in clinical programs and cash position reinforced
August 31, 2009
- Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates.
- Increase in operational loss, explained notably by the contractual end of the R&D collaboration agreement with Novo Nordisk A/S.
- Cash position reinforced through the early refund of €10.4m in research tax credit; cash runway into 2011.
- Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates.
- Increase in operational loss, explained notably by the contractual end of the R&D collaboration agreement with Novo Nordisk A/S.
- Cash position reinforced through the early refund of €10.4m in research tax credit; cash runway into 2011.
Visit the investor section to download the interim financial report.
| Download Area |
|---|
| PR in english |
| CP en français |
| Presentation: Analysts update H109 (in english) |